- FOLD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $28.5 million.
- FOLD has traded 4.2 million shares today.
- FOLD is trading at 2.60 times the normal volume for the stock at this time of day.
- FOLD is trading at a new high 8.13% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in FOLD with the Ticky from Trade-Ideas. See the FREE profile for FOLD NOW at Trade-Ideas More details on FOLD: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Currently there are 3 analysts that rate Amicus Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Amicus Therapeutics has been 2.3 million shares per day over the past 30 days. Amicus has a market cap of $432.9 million and is part of the health care sector and drugs industry. The stock has a beta of 1.76 and a short float of 8.1% with 0.28 days to cover. Shares are up 130.2% year-to-date as of the close of trading on Thursday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Amicus Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Highlights from the ratings report include:
- The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
- Net operating cash flow has decreased to -$11.82 million or 15.18% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 4.8% when compared to the same quarter one year prior, going from -$15.35 million to -$14.61 million.
- AMICUS THERAPEUTICS INC has improved earnings per share by 29.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, AMICUS THERAPEUTICS INC reported poor results of -$1.17 versus -$1.09 in the prior year. This year, the market expects an improvement in earnings (-$0.91 versus -$1.17).
- This stock has increased by 55.83% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in FOLD do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full Amicus Therapeutics Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.